Prognostic Importance of Advanced Age in Aggressive Non-Hodgkin’s Malignant Lymphoma

Oncology (Switzerland)

Volumn 53, Issue 6, 1996, Pages 435-440

  Kovner, F ^a   Merimsky, O ^a   Inbar, M ^a   Soyfer, V ^a   Cahan, Y ^b,c   Rachmani, R ^b,c   Chaitchik, S ^a  

^a Departments of Oncology   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Age; Chemotherapy; Dose intensity; Non Hodgkins lymphoma; Percentage dose intensity; Prognostic factors

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GROWTH FACTOR; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; HUMAN; MAXIMUM PERMISSIBLE DOSE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 0029969089     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227617     Document Type: Article

References (21)

1. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, et al: Comparison of a standard regimen (CHOP) with threee intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma, N Engl J Med 1993;328:1002-1006.
2. Ansell SM, Falkson G, van dcr Mere R, Uys A: Chronological age is a multifactorial prognostic variable in patients with non-Hodgkin’s lymphoma, Ann Oncol 1992;3:45-50.
3. Longo DL, Duffey PL, DcVita VT Jr., Wesley MN, Hubbard SM, Young RC:The calculation of actual or received dose intensity: A comparison of published methods, J Clin Oncol 1991;9: 2042-2051.
4. Gaynor ER, Dahlberg S, Fisher RI: Factors affecting reduced survival of the elderly with intermediate and high grade lymphoma, Proc Annu Meet Am Soc Clin Oncol 1994; 13: A1250.
5. Meyer RM, Bengcr A, Browman G, et al: Randomized phase II comparision of standard CHOP with weekly ‘CHOP’ for elderly patients with intermediate grade lymphoma, Proc Annu Meet Am Soc Clin Oncol 1994; 13:A1245.
6. Dixon DO, Neilan B, Jones SE, et al: Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma, J Clin Oncol 1986; 4:295-305.
7. Armitage JO, Potter JF: Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age, J Am GeriatrSoc 1984;32:269-273.
8. Vosc JM, Armitage JO, Weiscnbruger DD, et al: The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin’s lymphoma, J Clin Oncol 1988; 6:1838-1844.
9. Licht JD, Bosserman LD, Andersen JW, Yeap BY, et al: Treatment of low-grade and interme-diatc-gradc lymphoma with intensive combination chemotherapy results in long-term disease-free survival, Cancer 1990;66:632-639.
10. Bloomfield CD, Goldman A, Dick F, et al: Multivariate analysis of prognostic factors in the non-Hodgkin’s malignant lymphomas, Cancer 1974;33:870-879.
11. Fisher RI, Hubbard SM, de Vita VT, et al: Factors prediciting long term survival in diffuse mixed histiocytic or undifferentiated lymphoma, Blood 1981;58:45-51.
12. Gams RA, Rainey M, Dandy M, et al: Phase III study of BCOP vs CHOP in unfavorable categories of malignant lymphoma, J Clin Oncol 1985:3:1188-1195.
13. Stewart WP, Crowther D, McWilliam LJ, et al: Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histological type non-Hodgkin’s lymphoma, Cancer 1988;61:441-447.
14. Cowan RA, Jones M, Harris M, et al: Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma, Br J Cancer 1989;59: 276-282.
15. Velasquez WS, McLaughlin P, Fuller MN, et al: Intermediate grade lymphomas treated with cyclophosphamide - doxorubicin - vincristine -prednisone-blcomycin alternated with cyclophosphamide - methotrexate - etoposidc - dexa-mcthasone, Cancer 1994;73:2408-2416.
16. Bartlett NL, Kwak LW, Homing SJ: MACOP-B + radiation therapy for diffuse large cell lymphoma, Analysis of Stanford results according to prognostic indices, Cancer 1993,71:4034-4042.
17. Zagoncl V, Babare R, Mcrola MC, et al: Cost-benefit of granulocyte stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy, Ann Oncol 1994;5(suppl 2): 127-132.
18. O’Reilly SE, Connors JM, Howdle S, Hoskins P, Klasa R, Klimo P, Stuart DS: In search of an optimal regimen for elderly patients with advanced stage diffuse large cell lymphoma: Results of a phase II study of P/DOCE chemotherapy, J Clin Oncol 1993;11:2250-2257.
19. Gascoyne R, Hoskins P, Connors J, Coldman A, Klasa R, O’Reilly SE: A study of clinical and pathologic variables affecting disease-specific survival (DSS) of patients with diffuse large cell lymphoma treated with MACOP-B or VA-COP-B: Univariate and multivariate analyses, Proc Annu Meet Am Soc Clin Oncol 1994; 13: A1266.
20. Shipp MA, et al: A predictive model for aggressive non-Hodgkin's lymphoma, The International Non-Hodgkin’s Lymphoma Prognostic Factors Project, N Engl J Med 1993:329:987- 994.
21. Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, Mann R, Resnick GD, Barcos M, Gottlieb A, O’Connell M: Comparison of second-generation chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin’s lymphoma, N Engl J Med 1992:327:1342-1349.